No matter how cynical the overall market is BioXcel Therapeutics Inc (BTAI) performance over the last week is recorded -37.77%

On Tuesday, BioXcel Therapeutics Inc (NASDAQ: BTAI) opened lower -7.06% from the last session, before settling in for the closing price of $0.38. Price fluctuations for BTAI have ranged from $0.30 to $4.17 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 67.00%. Company’s average yearly earnings per share was noted 72.28% at the time writing. With a float of $41.08 million, this company’s outstanding shares have now reached $42.46 million.

The extent of productivity of a business whose workforce counts for 74 workers is very important to gauge. In terms of profitability, gross margin is 4.13%, operating margin of -3295.61%, and the pretax margin is -3119.33%.

BioXcel Therapeutics Inc (BTAI) Insider Updates

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of BioXcel Therapeutics Inc is 17.23%, while institutional ownership is 17.38%. The most recent insider transaction that took place on Dec 16 ’24, was worth 58. In this transaction an insider of this company sold 165 shares at a rate of $0.35, taking the stock ownership to the 19,957 shares. Before that another transaction happened on Dec 16 ’24, when Company’s CEO and President sold 3,117 for $0.36, making the entire transaction worth $1,131. This insider now owns 59,605 shares in total.

BioXcel Therapeutics Inc (BTAI) Performance Highlights and Predictions

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 72.28% per share during the next fiscal year.

BioXcel Therapeutics Inc (NASDAQ: BTAI) Trading Performance Indicators

Check out the current performance indicators for BioXcel Therapeutics Inc (BTAI). In the past quarter, the stock posted a quick ratio of 1.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.76.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.15, a number that is poised to hit -0.45 in the next quarter and is forecasted to reach -1.33 in one year’s time.

Technical Analysis of BioXcel Therapeutics Inc (BTAI)

The latest stats from [BioXcel Therapeutics Inc, BTAI] show that its last 5-days average volume of 1.24 million was inferior to 1.73 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 16.94%. Additionally, its Average True Range was 0.07.

During the past 100 days, BioXcel Therapeutics Inc’s (BTAI) raw stochastic average was set at 10.58%, which indicates a significant decrease from 15.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 193.54% in the past 14 days, which was higher than the 117.58% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $0.4803, while its 200-day Moving Average is $1.1257. Now, the first resistance to watch is $0.3837. This is followed by the second major resistance level at $0.4106. The third major resistance level sits at $0.4275. If the price goes on to break the first support level at $0.3399, it is likely to go to the next support level at $0.3230. Assuming the price breaks the second support level, the third support level stands at $0.2961.

BioXcel Therapeutics Inc (NASDAQ: BTAI) Key Stats

There are currently 49,629K shares outstanding in the company with a market cap of 17.70 million. Presently, the company’s annual sales total 1,380 K according to its annual income of -179,050 K. Last quarter, the company’s sales amounted to 210 K and its income totaled -13,650 K.